Bank of New York Mellon Corp Has $533,000 Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Bank of New York Mellon Corp grew its stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 58.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 230,593 shares of the company’s stock after buying an additional 84,984 shares during the period. Bank of New York Mellon Corp owned approximately 0.33% of Ventyx Biosciences worth $533,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. SG Americas Securities LLC acquired a new position in Ventyx Biosciences during the second quarter valued at approximately $32,000. Norden Group LLC acquired a new position in Ventyx Biosciences in the 1st quarter valued at $59,000. China Universal Asset Management Co. Ltd. raised its holdings in Ventyx Biosciences by 66.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,385 shares of the company’s stock worth $63,000 after acquiring an additional 4,553 shares during the period. Aigen Investment Management LP acquired a new position in Ventyx Biosciences during the 4th quarter worth $65,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Ventyx Biosciences during the first quarter valued at about $72,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Stock Performance

Shares of VTYX stock opened at $2.46 on Tuesday. The firm has a fifty day moving average of $2.28 and a 200-day moving average of $3.70. The stock has a market cap of $173.43 million, a price-to-earnings ratio of -0.76 and a beta of 0.37. Ventyx Biosciences, Inc. has a 52-week low of $1.79 and a 52-week high of $36.19.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.12. On average, sell-side analysts predict that Ventyx Biosciences, Inc. will post -2.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on VTYX shares. Canaccord Genuity Group cut their price objective on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Oppenheimer reduced their price objective on Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Thursday, June 6th. Wells Fargo & Company dropped their target price on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Finally, HC Wainwright reissued a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a report on Monday. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.29.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.